Safety
-
Rocephin (ceftriaxone sodium) IV and IM
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – February 2010
WARNINGS
Hypersensitivity
- As with other cephalosporins, anaphylactic reactions with fatal outcome have been reported, even if a patient is not known to be allergic or previously exposed.
-
-







